De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy.

Mashima T, Seimiya H, Tsuruo T. · 2009

Read De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. by Mashima T, Seimiya H, Tsuruo T. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2694429.txt.

Introduction

Mashima, Seimiya, and Tsuruo reviewed in 2009 the idea of starving cancers by blocking the fat-making machinery they depend on. Fast-growing tumor cells build their own fatty acids from scratch to supply membranes, fuel, and protein decoration. Most healthy adult tissues skip this work and simply take fats from food, keeping the machinery idled.

Two enzymes run the pathway. The first, ACC, converts a basic building block into malonyl-CoA. The second, FASN, stitches those units into long fatty acid chains. Cancer flips both on hard, and tumors lean on the flow for survival. That contrast, a busy pathway in tumors and a quiet one in normal tissue, is exactly what drug hunters want. The review surveys blockers of these enzymes and related steps, and weighs how selectively they might kill tumor cells.

Catalog record

CREATORMashima T, Seimiya H, Tsuruo T.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE22 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2694429

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy By T Mashima, H Seimiya, T Tsuruo Published in: British Journal of Cancer DOI: 10.1038/sj.bjc.6605007 ABSTRACT Enhanced lipid biosynthesis is a characteristic feature of cancer. Deregulated lipogenesis plays an important role in tumour cell survival. These observations suggest that enzymes in the lipid synthesis pathway would be rational therapeutic targets for cancer. To this end, we review the enzymes in de novo fatty-acid synthesis and related pathways. To establish an effective strategy in molecular cancer therapeutics, it is essential to identify characteristic features of the disease and to discover ways to selectively target them. Altered metabolism is one of the important features of cancer. Initially, Otto Warburg observed enhanced anaerobic glycolysis in cancer (Warburg, 1956). The elevated glucose catabolism produces an excess of the glycolytic end-product, pyruvate. Most of the pyruvate is converted to lactate, whereas some of it is converted to acetyl-CoA, which, in turn, is used in de novo fatty-acid synthesis (Figure 1). Highly proliferating cancer cells need to synthesise fatty acids de novo to continually provide lipids for membrane production. The synthesised fatty acids are also used for energy production through β-oxidation and lipid modification of proteins. De novo fatty-acid synthesis involves two key enzymes, acetyl-CoA carboxylase (ACC) and fatty-acid synthase (FASN). ACC carboxylates acetyl-CoA to form malonyl-CoA. The malonyl-CoA product is further converted by FASN to long-chain fatty acids. Most normal human tissues preferentially use dietary (exogenous) lipid for synthesis of new structural lipids, whereas de novo (endogenous) fatty-acid synthesis is usually suppressed, and FASN expression is maintained at low levels. By contrast, in cancer cells, de novo fatty-acid synthesis is commonly elevated and the supply of cellular fatty acid is highly dependent on the de novo synthesis. Therefore, deregulated de novo fatty-acid synthesis directly leads to cellular fatty-acid accumulation and affects fundamental cellular processes, including signal transduction and gene expression. Numerous studies have shown overexpression of FASN in various human epithelial cancers, including prostate, ovary, colon, lung, endometrium and stomach cancers (Kuhajda, 2000). Moreover, several reports have shown that FASN and related lipogenic enzymes play important roles in tumour cell survival at multiple levels. This minireview summarises recent advances in this field and provides a theoretical basis for the enzymes in lipogenic pathway as a new class of molecular targets to induce cancer selective cell death. REGULATION OF FASN AND DE NOVO FATTY-ACID SYNTHESIS PATHWAY IN CANCER The increased de novo fatty-acid synthesis is caused by multiple mechanisms, including increased expression of lipogenic enzymes. Among them, FASN overexpression is observed in a wide variety of human cancers. In cancer cells, transcriptional regulation of FASN gene is one of the important mechanisms of FASN overexpression (Kuhajda, 2006; Menendez and Lupu, 2007). The FASN expression is regulated by growth factors – growth factor receptors, including epidermal growth factor receptor (EGFR) and HER2, and steroid hormone – steroid hormone receptors, such as oestrogen receptor (ER), androgen receptor (AR) and progesterone receptor (PR). Downstream of the receptors, the phosphatidylinositol-3-kinase (PI3K)-Akt and mitogen-activated protein kinase (MAPK) are candidate signalling pathways that mediate FASN expression through the sterol regulatory element-binding protein 1c (SREBP-1c). However, the regulations of FASN expression by the growth factor receptors are not simple. For instance, mutual regulation between FASN and the growth factor-dependent signalling is suggested. HER2 induces FASN expression through the downstream PI3K signalling (Kumar-Sinha et al, 2003). Conversely, FASN-dependent regulation of HER2 expression has also been reported (Menendez et al, 2004). Recent reports have further shown that the FASN expression is not only controlled by SREBP-1c, but also by other transcription factors, such as the p53 family proteins and the lipogenesis-related nuclear protein, SPOT14, which is overexpressed in breast tumours (D’Erchia et al, 2006; Martel et al, 2006). As with these intracellular signalling molecules, extracellular tumour microenvironmental stresses play an important role in tumour-related FASN expression. Solid tumours are commonly characterised by a unique pathophysiological microenvironment, such as hypoxia, low pH, and nutrient starvation. This hostile microenvironment activates several intracellular signalling pathways that promote malignant progression. Hypoxia and low pH stress induce the FASN expression in cancer cells (Menendez et al, 2005; Furuta et al, 2008). Hypoxia upregulates SREBP-1, the major transcriptional regulator of the FASN gene, through phosphorylation of Akt. Apart from the transcriptional regulation of FASN, it is also controlled at the posttranslational levels. Graner et al showed that the isopeptidase USP2a (ubiquitin-specific protease-2a) interacts with and stabilises FASN protein in prostate cancer (Graner et al, 2004). In breast cancer BT-474 cells that overexpress HER2, the expression of FASN and ACC are not mediated by SREBP-1, but by a mammalian target of rapamycin (mTOR)-dependent selective translational induction (Yoon et al, 2007). A significant copy number gain of FASN gene is also observed in prostate adenocarcinoma (Shah et al, 2006). These observations suggest that tumour-related FASN overexpression could be regulated at multiple levels (Figure 1). FASN AND DE NOVO FATTY-ACID SYNTHESIS AS PROMISING TARGETS OF CANCER FASN is not only overexpressed in cancer, but it also plays an essential role in tumour growth and survival. Two well-known FASN inhibitors, the natural product cerulenin and the synthetic compound c75, have been studied. Treating tumour cells with pharmacological inhibitors of FASN effectively suppresses growth and induces apoptosis in breast cancer cells both in vitro and in vivo (Pizer et al, 2000). Similarly, FASN knockdown by specific siRNAs induces apoptosis in prostate cancer LNCaP cells (De Schrijver et al, 2003). By contrast, the RNAi-mediated inhibition of FASN did not affect growth rate or viability of nonmalignant cells. These data indicate that the elevated level of FASN observed in many cancers actually plays a predominant role in tumour growth and survival, suggesting that this enzyme could be a rational therapeutic target. Although the precise mechanisms of FASN inhibition-induced cell death in cancer cells still remain unknown, several possibilities have been proposed. Initial studies indicate that FASN inhibition accumulates the toxic intermediary metabolite, malonyl-CoA, which induces apoptosis, whereas pharmacological inhibition of ACC by 5-(tetradecyloxy)-2-furoic acid does not (Pizer et al, 2000). These studies suggest that malonyl-CoA accumulation, but not end-product fatty-acid depletion, could be a critical factor for apoptosis induction. However, studies with siRNAs revealed that, as with FASN inhibition, ACC inhibition triggers apoptosis in prostate and breast cancer cells, but not in nonmalignant cells (Brusselmans et al, 2005; Chajes et al, 2006). Inhibiting ACC expression results in a major decrease in the cellular pool of palmitic acid and apoptosis induction. Moreover, supplementing the culture medium with palmitic acid completely rescues cells from both ACC and FASN knockdown-induced apoptosis (Chajes et al, 2006). These observations re-emphasise the importance of end-product fatty-acid starvation to cell death. At the same time, these data suggest that, apart from FASN inhibition, ACC inhibition could also be a rational strategy to induce selective death of tumour cells. As described above, FASN and tumour-related survival signals are mutually regulated, and FASN controls HER2-dependent signalling. Besides the role of FASN-dependent fatty-acid synthesis in fatty-acid supply for membrane production and energy production through β-oxidation, FASN overexpression is further associated with palmitoylation of signalling proteins (Fiorentino et al, 2008). Interference of these pathways could also be involved in the FASN inhibition-induced selective cancer cytotoxicity. In

Read the complete text